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with evident disadvantages for patients and increased costs due to the eventuality of a second hospitalization for axillary surgery [5]. Frozen section and imprint cytology have been proposed as appealing alternative techniques to obtain an intraoperative examination of SLN, but their sensitivities vary widely among studies, ranging from 17% to 94% [3, 6, 7]. Hence these cost-saving methods do not guarantee the avoidance of a second 
surgery for patients. One-Step Nucleic Acid Amplification (OSNA) assay is a rapid and standardized molecular technique, which has been largely validated in literature for intraoperative SLN analysis in comparison with standard histology, thus providing an accurate tool for immediate decisions in management of the axilla [8, 9]. Aim of our study was to investigate advantages of 
OSNA beyond its high accuracy for the definitive assessment of nodal involvement, including the possibility of a one-step surgery for both lumpectomy and possible axillary dissection, and subsequent anticipation in the onset of systemic adjuvant therapy. The secondary aim was to provide a comprehensive cost analysis for OSNA, since cost-effectiveness of OSNA still remains largely unknown.
Methods
Study population and case selectionFrom January 2011 to December 2012, we have reviewed data of 253 consecutive breast cancer patients with clinically and sonographically negative axillary nodes, who underwent conservative breast surgery with SLN biopsy at the Breast Unit of “Luigi Sacco” University Hospital in Milan, Italy. In all cases the SLN 
was identified using 1.5 mCi/ml of colloidal human serum albumin labelled with 99mTc injected into the periareolar subdermal area with subsequent lymphoscintigraphy on the day before surgery, 
and with a gamma-probe (Bluetooth Neoprobe Gamma Detection 
System) during surgery. The lymphoscintigraphy was performed 
in another Institute (“Niguarda Ca’ Granda” Hospital, Milan, 
Italy) due to the lack of a Nuclear Medicine Department in our Breast Unit. The SLN biopsy was performed postoperatively in 
139 patients with standard HE plus IHC, by embedding the sliced 
lymph node in paraffin wax, taking two adjacent sections every 50 micron and staining one of them with HE and the other one 
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IntroductionIntraoperative assessment of nodal status should be recommended in breast conservative surgery, since it avoids a second operation for axillary dissection in case of Positive 
Sentinel Node (SLN), with a subsequent decreased psychological burden for patients, a reduction in re-hospitalization and related costs, and the avoidance of delay between surgery and the onset of adjuvant therapy [1-3]. The most frequent technique for assessing the presence of nodal involvement is 
the histopathological analysis with Hematoxylin and Eosin (HE) 
stain plus Immuno Histo Chemistry (IHC), but its intraoperative use requires a long time and a heavy involvement of Pathology Departments to obtain an accurate nodal status assessment, thus it is available in a few Breast Units only [1, 2, 4]. Therefore, a large part of Institutes are forced to analyze the SLN postoperatively, 
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with IHC for cytokeratin [1, 4]. For 114 patients SLN analysis 
was performed intraoperatively with OSNA system (Sysmex, 
Kobe, Japan) obtaining a definitive result about nodal status [8, 
11]. Nodal involvement has been defined as reported in Table 1 [10, 11]. For both groups of patients, axillary dissection has been performed in case of macrometastases only [12-14].
Study design and cost analysisFor each patient we recorded the age at diagnosis, the histological tumor type and  grade, the expression of 
progesterone/estrogen receptors, Ki67, Her2/neu status, and 
T staging on final pathology. These variables were compared between the two groups of patients to assess possible population heterogeneity. Then, nodal involvement, rates of second surgery and time between surgery and adjuvant therapy have been compared between histopathology- and OSNA-analyzed patients. Mean operative time and hospitalization duration have been recorded for each group of patients, and for both positive and negative SLN. In case of positive SLN diagnosed by standard histopathology, these variables have been further separated for 
first surgery and second surgery for axillary dissection.A cost analysis has been performed comparing OSNA and postoperative histopathological examination of SLN. For 
cost analysis the mean operative time (minutes) for the two groups of patients have been multiplied by the cost of 1 minute 
of surgery, according to the Cost Management Office of our Institute i.e. 6.8€ per minute, including staff, devices, drugs and sterilization costs. Lymphoscintigraphy costs, including 
the specific cost of the procedure, the cost of a dose of 99mTC, the cost of lymphoscintigraphy radiological reporting, and the cost of patients transport to the Department of Nuclear Medicine, have also been counted in the analysis. The total cost of lymphoscintigraphy was based on Lombardy Region rates registry for this procedure: 158€ per single procedure plus 40€ per patient for transport. Hospitalization costs have been calculated by multiplying the hospitalization days by the cost of 1 day of patient stay in the Surgery Department, according 
to the Cost Management Office of our Institute, i.e. 634€ per patient per day including costs of medical and non medical staff, drugs, medical device, clinical tests and accommodation. The analysis has been completed with the cost of examination 
of SLN by OSNA (372€ per lymph node) or by standard HE plus 
IHC (335€ per lymph node), including consumables, reagents, staff and depreciated costs. These data have been furnished by the Pathology Department of our Institute. In case of need for a second surgery for axillary dissection, the costs of the two surgical interventions and of the two hospitalizations have been 
summed. All costs have been expressed in euros (€).All these costs have been summed to obtain the total cost per patient, which was calculated for the four possible scenarios: 
positive SLN diagnosed on HE plus IHC, positive SLN analyzed 
with OSNA, negative SLN diagnosed on HE plus IHC, and negative SLN analyzed with OSNA. Total costs have been compared between  the two techniques in case of positive and negative SLN.
Statistical analysis
Student’s T test was used for continuous variables and Fisher exact test for categorical variables. The cost analysis has been 
performed by Student’s T test. A p value < 0.05 was considered 
statistically significant. All analyses were carried out using the 
Stata software version 11.0 (Stata Corp, Austin, TX, USA).
Results
Nodal involvement detectionThe HE and OSNA groups of patients were comparable for mean age of diagnosis, tumor size, grade, histological type, 
hormone receptors, Ki67 and Her2 status (Table 2). In 139 
cases of histopathology group, 15 macrometastases (10.79%) were detected. In 114 cases of OSNA group, 20 macrometastases 
(17.54%) were detected (Table 2). This difference was not 
statistically significant (p = 0.105). In all patients with a macro metastasis, axillary dissection was performed.
Re-intervention rates for axillary surgery and timing 
of adjuvant therapyIn HE group all the axillary dissections were necessarily performed with a second surgery, while with OSNA method a one-step surgery was possible in all cases. Therefore, the re-
intervention rate for axillary dissection was 10.79% (15/139) for 
HE and 0% (0/114) for OSNA, p = 0.0003. Consequently, mean time between initial surgery and the onset of adjuvant therapy 
resulted to be significantly higher in patients with metastatic SLN 
analysed by histopathology (38.5 days, ±16.1) compared to those 
analysed by OSNA (23.8 days, ±7.7), p < 0.0001, with a significant 
decrease in the delay before systemic therapy with OSNA (Table 
3). 
Surgery times and hospitalization stayMean surgery times in case of negative SLN were slightly 
higher with OSNA: 67.7 min (±17.8) versus 63 min (±19,2) for HE 
(p = 0.066). For positive SLN, summed times of first and second 
surgery were comparable in the two groups: 122 min (±27.6) in 
HE group vs. 111.5 min (±31.8) in OSNA group (p = 0.314). Mean 
hospitalization time was similar in case of negative SLN (2.3 days 
±1.1 for HE vs. 2.2 days ±0.7 for OSNA, p = 0.442), while it was 
significantly higher in histology group of patients for positive 
SLN (7.3 days ±1.4 vs. 4.7 days ±1.6, p < 0.0001).
Table 1: Definition of isolated tumor cells, micro- and macro metastases according to HE examination or OSNA technique.
Histopathology (HE 
plus IHC)
OSNA examination
Negative or ITC
Tumor cell deposits 
<0.2 mm
<250 mRNA copies/uL
Micrometastasis
Tumor cell deposits 
≥0.2 mm and <2 mm
250-5,000 mRNA 
copies/uL
Macrometastasis
Tumor cell deposits 
≥2 mm
>5,000 mRNA copies/uL
 ITC isolated tumor cells
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Table 2: Comparison of baseline features between histopathology and OSNA group of patients.
Characteristic
Histopathology (n=139) 
n, (%)
OSNA 
(n=114) 
n, (%)
p value
Mean age of diagnosis, year (range) 62 (38-82) 62.5 (29-83) 1.000
Tumor size 
    pTis
    pT1
    pT2
    pTx
33 (23.74%)
88 (63.31%)
15 (10.79%)
3 (2.16%)
24 (21.05%)
77 (67.54%)
12 (10.53%)
1 (0.88%)
0.825
Histological grade 
    G1
    G2
    G3
39 (28.06%)
65 (46.76%)
35 (25.18%)
37 (32.46%)
47 (41.23%)
30 (26.31%)
0.646
Tumor type
    Invasive ductal 
    Invasive lobular
    DCIS
96 (69.06%)
7 (5.04%)
36 (25.90%)
84 (73.68%)
5 (4.39%)
25 (21.93%)
0.759
Estrogen receptors
    Negative
    Positive
17 (12.23%)
122 (87.77%)
18 (15.79%)
96 (84.21%)
0.466
Progesterone receptors
    Negative
    Positive
42 (30.22%)
97 (69.78%)
35 (30.70%)
79 (69.30%)
1.000
Ki67
    ≤14%
    >14%
68 (48.92%)
71 (51.08%)
61 (53.51%)
53 (46.49%)
0.528
Her2/neu status
    Positive
    Negative
13 (9.35%)
126 (90.65%)
15 (13.16%)
99 (86.84%)
0.421
Sentinel node status
    Micrometastasis
    Macrometastasis
    Negative/ITC
3 (2.16%)
15 (10.79%)
121 (87.05%)
6 (5.27%)
20 (17.54%)
88 (77.19%)
0.105
ITC isolated tumor cells, DCIS ductal carcinoma in situ
Table 3: Rates of second surgery for axillary dissection and time between surgery and adjuvant therapy between histopathology and OSNA group of patients.
Histopathology OSNA p value
Second surgery for axillary dissection
n, (%)
15 (10.79%) 0 (0%) 0.0003
Time between surgery and adjuvant 
therapy (days)
38.5 (±16.1) 23.8 (±7.7) <0.0001
Cost analysisSurgery costs based on operative times and including the 
specific costs of SLN examination (335€ per node for HE plus IHC, 
372€ per node for OSNA) were 763.4€ (±130.6€) for histology and 832.4€ (±121€) for OSNA (p < 0.0001) in case of negative SLN. In case of positive SLN, the summed cost of surgery for HE group was 829.6€ (±188€), while cost for OSNA was 758.2€ 
(±216.2€), p = 0.315. Hospitalization costs in case of negative SLN resulted to be 1,458.2€ (±697.4€) for HE and 1,394.8€ (±443.8€) for OSNA, 
p=0.442; in case of positive SLN, these costs were 4,628.2€ 
(±896.6€) for HE and 2,979.8€ (±1,014.4€) for OSNA, p < 0.0001.
Total cost per patient, including surgery, hospitalization and 
fixed costs for lymphoscintigraphy and patient transport have been determined for each group and subsequently for each SLN status. In case of positive SLN total cost per patient was 5,990.8€ 
(±916.1€) for HE plus IHC vs. 4,308€ (±1,037.2€) with OSNA (p < 
0.0001); in case of negative SLN it was 2,419.6€ (±709.5€) for HE 
plus IHC vs. 2,425.2€ (±460€) with OSNA, p=0.947. All these data are reported in Table 4.
DiscussionHistopathological examination of SLN with HE staining 
and IHC is the most commonly used technique; however intraoperative step-sectioning every 50 micron of SLN is a strain on Pathology Departments resources and requires both a 
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specific team of pathologists, which is often unavailable, and long 
procedure times (mean time of 50 minutes) [1, 3]. Therefore in several Institutes intraoperative histopathological analysis of SLN is unfeasible, and a second surgery for axillary dissection in case of positive SLN is generally necessary, with disadvantages in terms of impact on the quality of patients life and second hospitalizations [15, 16]. To overcome these limitations, some alternative techniques have been proposed to assess the status of SLN, such as imprint cytology and frozen sections analysis. However, their sensitivities vary widely due to the lack of standardization and to lower accuracy [3, 17-22]. Particularly about imprint cytology, one of the largest meta-analysis on 31 studies showed a pooled overall sensitivity equal to 63% when used intraoperatively [7]. This sensitivity should be considered unacceptably low for a proper intraoperative evaluation of the axilla.In our series OSNA has demonstrated to be an accurate and standard technique for sentinel node assessment, as previously reported in several validation studies [8, 23-26]. Moreover, the use of OSNA has reduced our second surgery rate for axillary 
dissection from 10.79% to 0% (p = 0.0003) thanks to its high intraoperative accuracy, thus demonstrating a role of OSNA in reducing second hospitalizations, with subsequent reduced patients discomfort. Klingler, et al. [16] have shown a similar reduction in the re-intervention rate for axillary dissection 
by using OSNA intraoperatively (9% vs. 39% if OSNA was not 
performed, p < 0.01). Furthermore, this rapid decision-making on the axilla allows a prompt starting of adjuvant therapy, with 
significant reduction in time between surgery and adjuvant 
treatment in patients with an involved SLN (23.8 days in case of intraoperative OSNA vs. 38.5 days with postoperative 
histopathology, p < 0.0001).A less investigated feature of OSNA is cost-effectiveness, which is a matter of debate since OSNA is more expensive than morphological examination of the SLN [27]. A comprehensive 
cost-analysis of OSNA should include three levels of assessment: surgery costs, hospitalization costs, and pathological examination costs [27]. Surgery costs mainly vary as a function of the operative times, and in our series mean time of surgery was rather higher when including OSNA intraoperative assay 
(67.7 vs. 63 minutes without intraoperative assessment in case 
of negative SLN, p = 0.066). However, as expected, the two mean 
times were not significantly different, because in our centre the SLN biopsy is performed before the lumpectomy, and thus the waiting time of OSNA is spent in excision of the tumor without further elongation of surgery. For positive SLN patients mean operative times between the two groups were not different 
(111.5 vs. 122 minutes in HE and OSNA groups, respectively, p = 
0.314), because the longer time required by OSNA is balanced by the longer time required for a new surgical access to the axilla in 
case of a second surgery. Considering only operative times and 
specific examination costs, OSNA is therefore more expensive in 
case of negative SLN (832.4€ vs. 763.4€, p < 0.0001), but on the other hand it is comparable to histopathology in case of positive 
SLN (758.2€ vs. 829.6€, p = 0.315). As expected, mean hospitalization time was similar in the two 
groups in case of negative SLN (2.3 vs. 2.2 days), but increased 
significantly in histopathology group in case of positive SLN due 
to the need of readmission (7.3 vs. 4.7 days, p < 0.0001). As a consequence, hospitalization costs in case of negative 
SLN resulted to be similar between the two groups (1,458.2€ vs. 1,394.8€), but in case of the need of axillary dissection these costs 
markedly rise for HE group (4,628.2€ vs. 2,979.8€, p < 0.0001).
Considering surgery, hospitalization, pathology examination 
and fixed costs together, it was evident that OSNA is globally cost-effective compared to post-operative histopathology, since total costs were identical between the two groups of patients 
in case of negative SLN (2,419.6€ vs. 2,425.2€, p = 0.947), and strongly favourable for OSNA in case of positive SLN (4,308€ vs. 5,990.8€, p < 0.0001). These data suggest that, in case of a second 
Table 4:  Cost Analysis.
Histopathology (n = 139) OSNA (n = 114)
LNS+ 
(n=15)
Costs LNS- (n=124) Costs
LNS+ 
(n=20)
Costs
LNS- 
(n=94)
Costs
Mean operative time 
(first surgery) – 6.8€ 
per min
53.2 (±19.5)
361.8€ 
(±132.6€) 63 (±19.2) 428.4€ (±130.6€) 111.5 (±31.8) 758.2€ (±216.2€) 67.7 (±17.8) 460.4€ (±121€)
Mean hospitalization 
stay (first surgery) – 
634€ per day
2.4 (±1)
1,521.6€ 
(±634€) 2.3 (±1.1) 1,458.2€ (±697.4€) 4.7 (±1.6) 2,979.8€ (±1,014.4€) 2.2 (±0.7) 1,394.8€ (±443.8€)
Mean operative time 
(second surgery) – 
6.8€ per min
68.8 (±19.6)
467.8€ 
(±133.3€) - - - - - -
Mean hospitalization 
stay (second surgery) 
– 634€ per day
4.9 (±1)
3,106.6€ 
(±634€) - - - - - -
Total cost per 
patient*
5,990.8€ (±916.1€)** 2,419.6€ (±709.5€) 4,308€ (±1037.2€)** 2,425.2€ (±460€)
*Including lymphoscintigraphy and patient transport (158€ + 40€) and SLN analysis (HE plus IHC 335€, OSNA 372€).
**p < 0.0001
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hospitalization for further axillary surgery, global costs are not sustainable, and from this point of view OSNA becomes even more appealing.
Similar results have been reported in a recent cost-benefit French study in which the SLN has been analyzed by OSNA or by conventional post-operative histopathology [27]. The average pathology examination cost was markedly higher for OSNA 
(291.84€ vs. 35.04€); however, since the hospital stay was much longer in histopathology group due to re-hospitalization for 
axillary surgery (5.4 vs. 4.2 days), total cost of OSNA was lower compared to histopathology [27]. Notably, the reported costs for 
histopathology examination (35.04€) were much lower than that obtained in our study, but the Authors have not included staff 
costs. Interestingly, a significant cost difference between the two techniques was evident considering separately patients with or 
without axillary dissection, which was a common finding also in 
our study. Another relevant cost-benefit analysis by the Spanish 
group of Guillén-Paredes [28] has pointed out a reduction in total hospital stay with OSNA, saving up to 199.69€ per patient for hospitalization costs. Finally, a more complex analysis has been provided in a British study based on three different cost-analysis pathways: lumpectomy with axillary dissection, lumpectomy with SLN biopsy and postoperative histopathology, and lumpectomy with molecular analysis of the SLN [5]. Although this study demonstrated a substantial cost-effectiveness of molecular analysis compared to standard histopathology, it also highlighted that in some countries the avoidance of a second surgery with subsequent loss of reimbursement from National Health Services could discourage the adoption of intraoperative SLN examinations [5].
ConclusionOSNA is a standard and reproducible technique for highly accurate intraoperative examination of the SLN, comparable to postoperative histopathology with immunohistochemistry. 
Intraoperative use of OSNA significantly reduces the rate of second surgery for axillary dissection, with a strongly reduced discomfort for patients and a prompt start of adjuvant therapy. The charm of this technique also relies on its demonstrated cost-
effectiveness, which allows significant saving of money in case of nodal involvement due to the avoidance of a re-hospitalization.
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